Panel Discussion: Overcoming Sensitivity & Specificity Challenges to Deliver Reliable Liquid Biopsy Results at Scale

3:15 pm - Wednesday 4th February 2026

  • Defining and achieving the optimal analytical thresholds for sensitivity and specificity in line with intended clinical use – how sensitive is too sensitive?
  • Discussing strategies to minimize CHIP related false positives and false negatives without compromising turnaround time or trial feasibility
  • Refining analytical validation data strategies to support regulatory submissions, companion diagnostic partnerships, and confident clinical decision-making

Speakers:

Executive Director - Bioinformatics
Boundless Bio
Vice President - Translational Medicine
BBOT (BridgeBio Oncology Therapeutics)
Senior Vice President - Clinical Development, Population Health & Biostatistics
GRAIL